Del Mar Pharmaceuticals Inc. (DMPI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.30+0.05 (+0.95%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close5.25
Bid0.00 x
Ask0.00 x
Day's Range5.22 - 5.68
52wk Range0.75 - 10.87
1y Target EstN/A
Market Cap54.68M
P/E Ratio (ttm)-10.17
Avg Vol (3m)36,866
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire8 days ago

    DelMar Pharmaceuticals Presents Overview of VAL-083's Unique Anticancer Mechanism at the European Association of Neuro-Oncology (EANO) Annual Meeting

    VANCOUVER, British Columbia, and MENLO PARK, Calif., Oct. 17, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, is pleased to announce that the Company presented additional data regarding VAL-083's unique anti-cancer mechanism on Saturday October 15, 2016 at the 12th Meeting of the European Association of Neuro-Oncology (EANO) in Mannheim, Germany. "These data further differentiate VAL-083's mechanism of action against cancer from the current standard of care in the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer," said Dr. Dennis Brown, DelMar's Chief Scientific Officer. Temozolomide, the current front-line therapy generates its anti-tumor activity by methylation of the O6-position of guanine, resulting in a base-pair mismatch which can be lethal to the tumor cell if not repaired.  The majority of patients exhibit a high expression of the DNA repair enzyme "MGMT", which readily repairs temozolomide-derived DNA damage leading to tumor resistance and treatment failure.  GBM patients failing temozolomide have a very poor prognosis with median survival of 6 – 9 months.

  • PR Newswire12 days ago

    DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations

    VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 13, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ...

  • Three Cancer Plays For The Fourth Quarter Of 2016
    Insider Monkey20 days ago

    Three Cancer Plays For The Fourth Quarter Of 2016

    We are now into the final quarter of 2016, and there looks set to be plenty of activity across the biotech space before the year draws to a close. Companies with a range of target indications have near-term catalysts, but some of the most volatility inducing are rooted in oncology. Here are three companies with […]